Logo image of BMRA

BIOMERICA INC (BMRA) Stock Fundamental Analysis

NASDAQ:BMRA - Nasdaq - US09061H4065 - Common Stock - Currency: USD

3.64  +0.04 (+1.11%)

After market: 3.6 -0.04 (-1.1%)

Fundamental Rating

2

Overall BMRA gets a fundamental rating of 2 out of 10. We evaluated BMRA against 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for BMRA as it has an excellent financial health rating, but there are worries on the profitability. BMRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BMRA has reported negative net income.
In the past year BMRA has reported a negative cash flow from operations.
BMRA had negative earnings in each of the past 5 years.
In the past 5 years BMRA always reported negative operating cash flow.
BMRA Yearly Net Income VS EBIT VS OCF VS FCFBMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

BMRA's Return On Assets of -65.75% is on the low side compared to the rest of the industry. BMRA is outperformed by 73.02% of its industry peers.
Looking at the Return On Equity, with a value of -87.64%, BMRA is doing worse than 61.38% of the companies in the same industry.
Industry RankSector Rank
ROA -65.75%
ROE -87.64%
ROIC N/A
ROA(3y)-51.28%
ROA(5y)-46.48%
ROE(3y)-68.67%
ROE(5y)-61.12%
ROIC(3y)N/A
ROIC(5y)N/A
BMRA Yearly ROA, ROE, ROICBMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Gross Margin of BMRA (13.47%) is worse than 80.42% of its industry peers.
BMRA's Gross Margin has declined in the last couple of years.
BMRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.97%
GM growth 5Y-14.58%
BMRA Yearly Profit, Operating, Gross MarginsBMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

BMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BMRA remains at a similar level compared to 1 year ago.
BMRA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BMRA Yearly Shares OutstandingBMRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
BMRA Yearly Total Debt VS Total AssetsBMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -7.58, we must say that BMRA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.58, BMRA is doing worse than 76.19% of the companies in the same industry.
There is no outstanding debt for BMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.58
ROIC/WACCN/A
WACC9.1%
BMRA Yearly LT Debt VS Equity VS FCFBMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 3.76 indicates that BMRA has no problem at all paying its short term obligations.
BMRA has a better Current ratio (3.76) than 62.96% of its industry peers.
A Quick Ratio of 2.76 indicates that BMRA has no problem at all paying its short term obligations.
BMRA's Quick ratio of 2.76 is fine compared to the rest of the industry. BMRA outperforms 60.85% of its industry peers.
Industry RankSector Rank
Current Ratio 3.76
Quick Ratio 2.76
BMRA Yearly Current Assets VS Current LiabilitesBMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.09% over the past year.
The Revenue has been growing slightly by 5.07% in the past year.
The Revenue has been growing slightly by 0.81% on average over the past years.
EPS 1Y (TTM)26.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.71%
Revenue 1Y (TTM)5.07%
Revenue growth 3Y-9.06%
Revenue growth 5Y0.81%
Sales Q2Q%10.03%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMRA Yearly Revenue VS EstimatesBMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BMRA Yearly EPS VS EstimatesBMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2018 2019 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMRA Price Earnings VS Forward Price EarningsBMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMRA Per share dataBMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BMRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMERICA INC

NASDAQ:BMRA (5/20/2025, 8:00:01 PM)

After market: 3.6 -0.04 (-1.1%)

3.64

+0.04 (+1.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-14 2025-04-14
Earnings (Next)08-26 2025-08-26
Inst Owners11.9%
Inst Owner Change-31.44%
Ins Owners10.82%
Ins Owner Change25.81%
Market Cap9.28M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short Ratio0.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.63
P/FCF N/A
P/OCF N/A
P/B 1.68
P/tB 1.75
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS2.23
BVpS2.17
TBVpS2.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.75%
ROE -87.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.47%
FCFM N/A
ROA(3y)-51.28%
ROA(5y)-46.48%
ROE(3y)-68.67%
ROE(5y)-61.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.97%
GM growth 5Y-14.58%
F-Score4
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.98%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.76
Quick Ratio 2.76
Altman-Z -7.58
F-Score4
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)60.25%
Cap/Depr(5y)97.47%
Cap/Sales(3y)1.51%
Cap/Sales(5y)2.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.71%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.07%
Revenue growth 3Y-9.06%
Revenue growth 5Y0.81%
Sales Q2Q%10.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.84%
OCF growth 3YN/A
OCF growth 5YN/A